Please use this identifier to cite or link to this item:
https://saber.ucv.ve/jspui/handle/10872/23306Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Ponte-Sucre, Alicia | - |
| dc.date.accessioned | 2024-12-10T19:29:20Z | - |
| dc.date.available | 2024-12-10T19:29:20Z | - |
| dc.date.issued | 2024-12-10 | - |
| dc.identifier.uri | http://hdl.handle.net/10872/23306 | - |
| dc.language.iso | es | en_US |
| dc.relation.ispartofseries | MiradorSalud;22 de junio de 2021 | - |
| dc.subject | Covid | en_US |
| dc.subject | farmacología | en_US |
| dc.subject | terapéutica | en_US |
| dc.title | Molnupiravir el más avanzado de los antivirico en desarrollo | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Artículos de Prensa | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Molnupiravir. El más avanzado antivítrico_APS....pdf | 141.46 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.